June 25, 2008 – Xoft Inc. launched the EXIBT Study (Electronic Xoft Intersociety Brachytherapy Trial), a national Electronic Brachytherapy patient registry under oversight from three national physician societies, the American Brachytherapy Society (ABS), the American Society of Breast Surgeons (ASBrS) and the American College of Radiation Oncology (ACRO).
The first patient was successfully enrolled and treated in the registry by Peter Beitsch, M.D., of the Dallas Breast Center and Timothy Nichols, M.D., of the Northpoint Cancer Center in Dallas, TX.
With an enrollment goal of 400 patients, the objective of the multi-center study is to assess the long-term safety and efficacy of the Xoft Axxent Electronic Brachytherapy System for the treatment of early stage breast cancer patients. The primary endpoint is the measurement and quantification of skin and subcutaneous toxicities through five-year follow-up. An additional primary endpoint includes a quality of life questionnaire based on patient experience with this new form of radiation therapy. Secondary endpoints assess local-regional breast failure and patient survival through five years as well as device performance.
“From earlier diagnosis to decreased morbidities and treatment times and ultimately, improved survival, we have made great strides in treating women with breast cancer,” said Dr. Beitsch, co-Principal Investigator of EXIBT and the surgeon for the first patient on the registry. “For many women, post lumpectomy radiation therapy can now be completed in one week with brachytherapy compared to the six to seven weeks required for external beam therapy.”
For more information: www.xoftinc.com